Predictive Therapy Response Technology Patent Portfolio


47 Assets with 3 Representative Claim Charts

The offered assets of BioMarker Strategies comprise a portfolio in the Predictive Therapy Response technology domain. The portfolio relates to predicting therapy response in cancer and is directed toward improved methods and devices for analyzing a cell, aggregated cells, or a solid tumor (SnapPath® family) and compositions and methods for prediction of drug sensitivity, resistance, and disease progression (PathMAP® family). The technical solutions described in the patents have been widely adopted by biotech companies trying to predict the effectiveness of targeted therapies.